Compare Citius Pharmaceuticals Inc (CTXR) vs PAGSEG Inc (PAGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs PAGSEG Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.54 (market cap $14.64M), while PAGSEG Inc trades at $9.25 (market cap $2.59B). The key difference: PAGSEG Inc is far larger — about 176.9× Citius Pharmaceuticals Inc's market cap, and PAGSEG Inc pays a 11.21% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | PAGS | |
|---|---|---|
Market Cap | $14.64M | $2.59B |
Sector | Health | Technology |
52-Week High | $1.82 | $12.00 |
52-Week Low | $0.53 | $7.75 |
Enterprise Value | $10.86M | $10.22B |
Dividend Yield | — | 11.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
PAGS trades at $9.28, up 0.32% on the day, with a bullish technical signal from moving averages. The stock shows strong value metrics with a P/E of 6.57 and P/S of 0.68, supported by solid profitability including a 10.4% net income margin. Recent Q1 2026 earnings missed expectations at $0.39 per share versus $0.40 expected, but Q4 2025 beat estimates. The company maintains robust cash flow from operations of $7.56 billion in 2025.
Outlook remains positive due to deep valuation discounts and analyst consensus favoring buys (62.5%). Key risks include Brazilian macroeconomic sensitivity and competitive pressures in digital banking. Upside potential hinges on execution in credit expansion and efficiency gains, with the stock positioned for recovery if rate cuts materialize in Brazil.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About PAGSEG Inc
PagSeguro Digital Ltd. is a leading provider of financial technology solutions in Brazil, primarily focused on e-commerce, face-to-face transactions, and financial services. The company's main offerings include PagBank, a digital banking platform, and PagSeguro, a suite of payment processing solutions that includes point-of-sale devices and online payment gateways. PAGS targets micro-merchants, small and medium-sized enterprises (SMEs), and consumers, aiming to democratize access to financial services in the country.
Read more on PAGS →
